Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy

(2018) Chih-Wei Lin et al.   CLINICAL THERAPEUTICS

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

(2018) Hiddo J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Baseline characteristics and enrichment results from the SONAR trial

(2018) Hiddo J.L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine

(2015) Hiddo J. Lambers Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

(2014) D. de Zeeuw et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Dose-Dependent Acute and Sustained Renal Effects of the Endothelin Receptor Antagonist Avosentan in Healthy Subjects

(2009) J Smolander et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria

(2009) R. R. Wenzel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY